drugset / Trial / NCT00251797
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the combination of drugs cause? 4. How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
Timeline
- Start
- 2000-03
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 300 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 350 mg/m2 | Intravenous |
| Subject | Thalidomide | Other / unclassified | 200 mg | Oral |